Porton Pharma Solutions

CAS 129722-34-5

Chemistry, 7 End Use API, 54 Related Intermediates

Manufacturers/Suppliers

7 Suppliers

7 Suppliers

Also known as: 129722-34-5, 3,4-dihydro-7-(4-bromobutoxy)-2(1h)-quinolinone, 7-(4-bromobutoxy)-3,4-dihydro-2(1h)-quinolinone, 7-(4-bromo-butoxy)-3,4-dihydro-1h-quinolin-2-one, 7-(4-bromobutoxy)-3,4-dihydro-2-quinolinone, 7-(4-bromobutoxy)-3,4-dihydro-1h-quinolin-2-one

Molecular Formula

C₁₃H₁₆BrNO₂

Molecular Weight

298.18 g/mol

InChI Key

URHLNHVYMNBPEO-UHFFFAOYSA-N

1 2D Structure

CAS 129722-34-5

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

7-(4-bromobutoxy)-3,4-dihydro-1H-quinolin-2-one

2.1.2 InChI

InChI=1S/C13H16BrNO2/c14-7-1-2-8-17-11-5-3-10-4-6-13(16)15-12(10)9-11/h3,5,9H,1-2,4,6-8H2,(H,15,16)

2.1.3 InChI Key

URHLNHVYMNBPEO-UHFFFAOYSA-N

2.1.4 Canonical SMILES

C1CC(=O)NC2=C1C=CC(=C2)OCCCCBr

2.2 Synonyms

2.2.1 Depositor-Supplied Synonyms

1. 129722-34-5

2. 3,4-dihydro-7-(4-bromobutoxy)-2(1h)-quinolinone

3. 7-(4-bromobutoxy)-3,4-dihydro-2(1h)-quinolinone

4. 7-(4-bromo-butoxy)-3,4-dihydro-1h-quinolin-2-one

5. 7-(4-bromobutoxy)-3,4-dihydro-2-quinolinone

6. 7-(4-bromobutoxy)-3,4-dihydro-1h-quinolin-2-one

7. 2(1h)-quinolinone, 7-(4-bromobutoxy)-3,4-dihydro-

8. (1h)-7-(4'-bromobutoxy)-3,4-dihydro-2-quinolinone

9. 7-(4-bromobutoxy)-3,4-dihydroquinolinone

10. 7-(4-bromobutoxy)-3,4-dihydroquinolin-2-one

11. Mfcd06658540

12. 7-(4-bromobutoxy)-2(1h)-3,4-dihydroquinolinone

13. Aripiprazole Impurity

14. Aripiprazole Intermediates

15. Schembl8513

16. 7-(4-bromobutoxy)-1,2,3,4-tetrahydro-2-oxoquinoline

17. Dtxsid00441550

18. Bcp08864

19. Cs-d1542

20. Bbl011057

21. Stk802231

22. Zinc15919788

23. Akos005622563

24. Ac-8060

25. Sb32672

26. 7-(4-bromobutoxy)-3,4-dihydroquinolin-

27. 7-(4bromobutoxy)-3,4-dihydrocarbostyril

28. Aripiprazole Bromobutoxyquinoline Impurity

29. As-14609

30. Sy023585

31. 7-(4-bromobutoxy) 3,4-dihydrocarbostyril

32. 7-(4-bromobutoxy)-3,4-dihydrocarbostyril

33. Db-017885

34. Am20090765

35. B3333

36. Ft-0643115

37. 722b345

38. A805968

39. 7-(4-bromo-butoxy)-3,4-dihydro-1h-quinolin-2one

40. A1-01685

41. 7-(4-bromobutoxy)-1,2,3,4-tetrahydroquinolin-2-one

42. 7-(4-bromobutoxy)-3,4-dihydroquinolin-2-one-[d8]

43. 7-(4-bromobutoxy)-1,2,3,4-tetrahydroquinoline-2-one

44. F2135-0630

45. 7-(4-bromobutoxy)-3,4-dihydro-1h-quinolin-2-one;7-(4-bromobutoxy)-3,4-dihydroquinolin-2(1h)-one

46. 7-(4-bromobutoxy)-3,4-dihydroquinolin-2-one; 3,4-dihydro-7-(4-bromobutoxy)-2(1h)-quinolinone; 7-(4-bromobutoxy)-3,4-dihydroquinolin-2(1h)-one

2.3 Create Date

2006-10-25

3 Chemical and Physical Properties

Molecular Formula	C₁₃H₁₆BrNO₂
Molecular Weight	298.18 g/mol
XLogP3	2.5
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	2
Rotatable Bond Count	5
Exact Mass	297.03644 g/mol
Monoisotopic Mass	297.03644 g/mol
Topological Polar Surface Area	38.3 Å²
Heavy Atom Count	17
Formal Charge	0
Complexity	260
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

Reset Filter

Ask Us

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

China

Virtual Booth

Digital Content

trans-2-(4-acetamidocyclohexyl)acetic acid

PDF Supplier PDF

URL Supplier Web Content

CAS Number

2901-44-2

End Use API

Cariprazine Hydrochloride

About the Company

Porton Pharma Solutions Ltd. was founded in 2005, & the company's stock was successfully listed in Shenzh...

Porton Pharma Solutions Ltd. was founded in 2005, & the company's stock was successfully listed in Shenzhen Stock Exchange in 2014. Our R&D, manufacturing & operation facilities are located in China, Slovenia, the US, Belgium, Switzerland, Denmark, with more than 6000 employees worldwide. Porton leads the way with its excellent CDMO services, but also supplies APIs & intermediates for the treatment of critical diseases such as HIV/AIDS, diabetes, cancer, & influenza. Our Process Technology Centers & WHO/USFDA/EMA/PDMA/NMPA-inspected Facilities feature state-of-the-art equipment, highly flexible cGMP-compliant production assets.

ASK
US